Navigation Links
Schizophrenic in Medical News

Improving the prognosis for schizophrenic disorders

Throughout the world, scientists are attempting to recognize and treat schizophrenic disorders at an earlier stage. It is hoped that this will improve the prognosis, which has often been unfavorable. In the latest edition of Deutsches rzteblatt International ( Dtsch Arztebl Int 2008; 105[30]: 5...

Cognitive rehabilitation holds promise for schizophrenic brain function improvements

Study had shown that it is possible to improve the brain functions of schizophrenic// patients through cognitive rehabilitation programs. Researchers from Washington University in St. Louis have suggested that memorization strategies used by normal people to remember things may be useful for s...

Music to help schizophrenic patients

Scientists have found that in addition to schizophrenic patients being given medical care, music, as a therapy, can bring about changes in their general sense of well being, mental state and social activities.// Since 1950s music had been used as a therapy for people with serious mental disord...

Alexza to Announce 2009 Second Quarter Financial Results and Update Its Clinical Pipeline Status on Wednesday, August 5, 2009

...comfort and convenience. Alexza's lead program is AZ-004 ( Staccato loxapine) and is being developed for the acute treatment of agitation in schizophrenic or bipolar disorder patients. Alexza has completed and announced positive results from both of its AZ-004 Phase 3 clinical trials, and is projecting ...

Columbia leads national effort to develop early intervention for schizophrenia

...ders by dramatically slowing progression; reducing disability, mortality, and the expense of care; and increasing recovery. The Recovery After Initial schizophrenic Episode (RAISE) study, funded at $9.9 million for two years, has the potential to be extended to six years and a total of $21.3 million if certain mil...

Study finds cancer is the second most frequent cause of death in individuals with schizophrenia

...tify characteristics that might help predict which schizophrenic patients are likely to develop cancer. The rese...he general population (56.3 vs. 33.0%). In female schizophrenic patients, the risk of death due to breast cancer w...ing less attention to symptoms; the difficulty for schizophrenic patients to benefit from optimum treatment; and le...

Alexza Announces Agreement to Acquire Symphony Allegro, Including All Rights to AZ-004, AZ-104 and AZ-002

...t comfort and convenience. Alexza's lead program is AZ-004 ( Staccato loxapine) and is being developed for the acute treatment of agitation in schizophrenic or bipolar disorder patients. Alexza has completed and announced positive results from both of its AZ-004 Phase 3 clinical trials, and is projecting ...

Alexza's Corporate Presentation to be Webcast at the Piper Jaffray Fourth Annual Europe Conference

...t comfort and convenience. Alexza's lead program is AZ-004 ( Staccato loxapine) and is being developed for the acute treatment of agitation in schizophrenic or bipolar disorder patients. Alexza has completed and announced positive results from both of its AZ-004 Phase 3 clinical trials, and is projecting ...

Favorable Vote From FDA Advisory Committee on SEROQUEL Pediatric Supplemental New Drug Applications

...including SEROQUEL. The relationship of atypical use and glucose abnormalities is complicated by the possibility of increased risk of diabetes in the schizophrenic population and the increasing incidence of diabetes in the general population. However, epidemiological studies suggest an increased risk of treatmen...

Alexza's Corporate Presentation to be Webcast at the Eighth Annual JMP Securities Research Conference

...t comfort and convenience. Alexza's lead program is AZ-004 ( Staccato loxapine) and is being developed for the acute treatment of agitation in schizophrenic or bipolar disorder patients. Alexza has completed and announced positive results from both of its AZ-004 Phase 3 clinical trials, and is projecting ...

More>>

Schizophrenic in Medical Technology

Alexza's AZ-004 (Staccato(R) Loxapine) Phase 3 Trial Meets Primary Endpoint of Treating Acute Agitation in Schizophrenic Patients

Conference Call Scheduled for Today - Tuesday, September 2, 2008 at 5:00 p.m. Eastern Time MOUNTAIN VIEW, Calif., Sept. 2 /PRNewswire-FirstCall/ -- Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA ) today announced positive results from its first Phase 3 clinical trial of ...

Alexza Reports 2009 First Quarter Financial Results and Updates Clinical Pipeline Status

...t comfort and convenience. Alexza's lead program is AZ-004 ( Staccato loxapine) and is being developed for the acute treatment of agitation in schizophrenic or bipolar disorder patients. Alexza has completed and announced positive results from both of its AZ-004 Phase 3 clinical trials, and is projecting ...

Omeros Receives $3.1 Million Milestone Payment from The Stanley Medical Research Institute for Schizophrenia Program

...of patients experience continued symptoms despite treatment. The problem with current therapies is that none of them improve the cognitive deficit in schizophrenic patients, and almost all of these drugs have significant side effects, such as weight gain, induction of tremors and psychological depression. ...

Alexza Initiates AZ-104 (Staccato(R) Loxapine) Phase 2b Clinical Trial in Patients With Migraine Headaches

...ndidates in clinical development. Alexza's lead program is AZ-004 (Staccato loxapine) that is being developed for the acute treatment of agitation in schizophrenic or bipolar disorder patients. Alexza has completed and announced positive initial results from both of its AZ-004 Phase 3 clinical trials, and is pro...

Alexza's AZ-004 (Staccato(R) Loxapine) Meets Primary Endpoint of Treating Acute Agitation in Patients with Bipolar Disorder in Phase 3 Trial

... the positive data from our first Phase 3 trial in schizophrenic patients -- reinforce our belief that AZ-004 is a ...olunteers, a 129 patient Phase 2 study in agitated schizophrenic patients, a 32 patient multiple-dose tolerability and pharmacokinetic study in non-agitated schizophrenic patients, a 344 patient Phase 3 study in schizophr...

AstraZeneca and Targacept Announce Top-Line Results from Phase IIb Study of AZD3480 in Cognitive Dysfunction in Schizophrenia

...mpairments play a primary role in the inability of schizophrenic patients to function normally. It has been estimated that there are 7.9 million schizophrenic patients in the world's seven major pharmaceutical markets and that the majority of all schizophrenic patients are cognitively impaired. About...

Alexza Reports 2008 Second Quarter Financial Results and Updates Development of Product Candidates

... developed for the treatment of acute agitation in schizophrenic or bipolar disorder patients," said Thomas B. King...ollment in its first Phase 3 clinical trial of 344 schizophrenic patients with acute agitation at 24 U.S. clinical ... loxapine) for the treatment of acute agitation in schizophrenic or bipolar disorder patients, is in Phase 3 testin...

Alexza Initiates Second Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine)

...olunteers, a 129 patient Phase 2 study in agitated schizophrenic patients, a 32 patient multiple-dose tolerability and PK study in non-agitated schizophrenic patients, and a 344 patient Phase 3 study in agitated schizophrenic patients. Alexza projects that the initial results...

Alexza Pharmaceuticals to Present AZ-104 Phase 2a Clinical Data at the American Headache Society Annual Scientific Meeting

... Alexza has six product candidates in clinical development. Alexza's lead program, AZ-004 (Staccato loxapine) for the treatment of acute agitation in schizophrenic or bipolar disorder patients, is in Phase 3 testing and has completed the enrollment of its first Phase 3 clinical trial. AZ-001 (Staccato prochlorper...

Alexza Completes Enrollment in Phase 3 Clinical Trial with AZ-004 (Staccato(R) Loxapine) for Acute Agitation

... Phase 2 study, and a 32 patient multiple-dose tolerability and PK study in schizophrenic patients. The Company believes that the unique delivery of loxapine via t...program, AZ-004 (Staccato loxapine) for the treatment of acute agitation in schizophrenic or bipolar disorder patients, is in Phase 3 testing. AZ-001 (Staccato proch...
Schizophrenic in Biological News

Advances in the field of schizophrenia research: New genetic factors identified

...ding to estimates, approximately one in every hundred persons experiences a schizophrenic episode at least once in their lives. In Germany alone there are approximat...proximately 80 percent according to estimations. Thus, close relatives of a schizophrenic patient are more susceptible to fall ill themselves. The hereditary pattern...

Scientists dig deeper into the genetics of schizophrenia by evaluating microRNAs

...ticular gene, such as BRAC1, can be tested and then treated with protocols designed specifically for them, we want to be able to know enough about the schizophrenic brain to target treatments to individual patients. The next step for the researchers is to find the many genes whose expression is controlled by t...

New treatment mechanisms for schizophrenia

...chizophrenia. These findings suggest that 7 nAChR agonists including SSR180711 could be potential therapeutic drugs for cognitive deficits in schizophrenic patients. In the third investigation, Semenova and colleagues show that a recently discovered brain receptor for serotonin (5-HT7) might be of impo...

The influence of the menstrual cycle on the female brain

...can result in disorders such as addictions and is also implicated in various psychiatric and neurological pathologies, such as Parkinson's disease and schizophrenic disorders. Many studies on animals prove that the dopaminergic3 system is sensitive to gonadal steroid hormones (estrogen, progesterone). For example,...

Engineered mouse mimics cognitive aspects of schizophrenia

...cs. The achievement is important, because creating an animal model of any schizophrenic characteristics has not been done before. And schizophrenia's genetic and p...neurons. Also, amphetamines, which release dopamine, are known to aggravate schizophrenic symptoms. The researchers also based their experiments on evidence that ...
Schizophrenic in Biological Technology

Alexza to Announce 2009 First Quarter Financial Results and Update Its Clinical Pipeline Status on Thursday, May 7, 2009

...t comfort and convenience. Alexza's lead program is AZ-004 ( Staccato loxapine) and is being developed for the acute treatment of agitation in schizophrenic or bipolar disorder patients. Alexza has completed and announced positive results from both of its AZ-004 Phase 3 clinical trials, and is projecting ...

Alexza's Corporate Presentation to be Webcast at the Future Leaders in the Biotech Industry Conference

...t comfort and convenience. Alexza's lead program is AZ-004 ( Staccato loxapine) and is being developed for the acute treatment of agitation in schizophrenic or bipolar disorder patients. Alexza has completed and announced positive results from both of its AZ-004 Phase 3 clinical trials, and is projecting ...

Alexza's Corporate Presentation to be Webcast at the 11th Annual BIO CEO & Investor Conference

...ent comfort and convenience. Alexza's lead program is AZ-004 (Staccato loxapine) and is being developed for the acute treatment of agitation in schizophrenic or bipolar disorder patients. Alexza has completed and announced positive results from both of its AZ-004 Phase 3 clinical trials, and is projecting ...

Alexza Consolidates Operations to Focus Resources on AZ-004 (Staccato(R) Loxapine) for Acute Agitation

...ent comfort and convenience. Alexza's lead program is AZ-004 (Staccato loxapine) and is being developed for the acute treatment of agitation in schizophrenic or bipolar disorder patients. Alexza has completed and announced positive initial results from both of its AZ-004 Phase 3 clinical trials, and is pro...

Azur Pharma Announces the Licensing of Niravam, Parcopa, Kemstro and Fluxid From UCB

...ro are central nervous system ("CNS") products. Azur Pharma's CNS business currently markets FazaClo(R) in the U.S. for the management of severely ill schizophrenic patients who fail to respond adequately to standard schizophrenia drug treatments. FazaClo is supplied as an innovative orally disintegrating tablet t...

FDA Approves AstraZeneca's SEROQUEL XR(R) for the Treatment of Bipolar Depression and Bipolar Mania

...ncluding quetiapine. The relationship of atypical use and glucose abnormalities is complicated by the possibility of increased risk of diabetes in the schizophrenic population and the increasing incidence of diabetes in the general population. However, epidemiological studies suggest an increased risk of treatment...

Alexza Pharmaceuticals Announces Upcoming Webcasts and Conference Participation

... has five product candidates in active clinical development. Alexza's lead program, AZ-004 (Staccato loxapine) for the treatment of acute agitation in schizophrenic or bipolar disorder patients, is in Phase 3 testing and has completed enrollment of its first Phase 3 clinical trial. A second Phase 3 clinical trial ...

Alexza to Announce 2008 Second Quarter Financial Results and Update Its Clinical Pipeline on Wednesday, August 6, 2008

... Alexza has six product candidates in clinical development. Alexza's lead program, AZ-004 (Staccato loxapine) for the treatment of acute agitation in schizophrenic or bipolar disorder patients, is in Phase 3 testing and completed the enrollment of its first Phase 3 clinical trial in June 2008. AZ-001 (Staccato pr...

Christopher Kurtz Joins Alexza Pharmaceuticals as Vice President, Global Supply Chain and Sustainment Engineering

... Alexza has six product candidates in clinical development. Alexza's lead program, AZ-004 (Staccato loxapine) for the treatment of acute agitation in schizophrenic or bipolar disorder patients, is in Phase 3 testing and has completed the enrollment of its first Phase 3 clinical trial. AZ-001 (Staccato prochlorper...

Alexza Reports 2008 First Quarter Financial Results and Updates Development of Product Candidates

...its first Phase 3 clinical trial, designed to enroll approximately 300 schizophrenic patients with acute agitation at 25 U.S. clinical centers. The trial ...program, AZ-004 (Staccato loxapine) for the treatment of acute agitation in schizophrenic or bipolar disorder patients, is in Phase 3 testing. AZ-001 (Staccato proch...
Other Tags
(Date:8/28/2015)... , ... August 28, 2015 ... ... for Medical Devices:, Understanding the FDA’s Position and Best Practices for Compliance, ... http://www.fdanews.com/cybersecuritymd , This workshop, chaired by internationally renowned expert Fubin Wu, ...
(Date:8/28/2015)... ... August 28, 2015 , ... On May 30th, 2015, Best Drug Rehabilitation, ... the “Music With A Mission” benefit concert in Mendon, IL. Held in the Show ... money to support music education programs in the underfunded local school districts of Mendon ...
(Date:8/28/2015)... , ... August 28, 2015 , ... “ Frequentz ” ... at the latest and coolest applications on the market for iOS, Android, and Windows. ... shared with viewers how this software allows businesses to track product movement from beginning ...
(Date:8/28/2015)... ... 28, 2015 , ... Medical Solutions, one of the nation’s largest travel nurse ... Healthcare by Modern Healthcare and will be honored at an awards dinner in ... the Best Places to Work in Healthcare program recognizes outstanding employers in the healthcare ...
(Date:8/28/2015)... (PRWEB) , ... August 28, 2015 , ... Dr. Gregory ... such as radiating pain resulting in shoulder pain, hip pain, neck pain, ... in Civil Engineering from the University of Illinois, and then went on to earn ...
Breaking Medicine News(10 mins):Health News:FDAnews Announces — Software and Cybersecurity Risk Management for Medical Devices: Understanding the FDA’s Position and Best Practices for Compliance, Oct. 14-15 2Health News:FDAnews Announces — Software and Cybersecurity Risk Management for Medical Devices: Understanding the FDA’s Position and Best Practices for Compliance, Oct. 14-15 3Health News:FDAnews Announces — Software and Cybersecurity Risk Management for Medical Devices: Understanding the FDA’s Position and Best Practices for Compliance, Oct. 14-15 4Health News:FDAnews Announces — Software and Cybersecurity Risk Management for Medical Devices: Understanding the FDA’s Position and Best Practices for Compliance, Oct. 14-15 5Health News:New Video Released on "Music With A Mission" Benefit Concert Headlining Artist Cadillac Three & Best Drug Rehabilitation 2Health News:Track Product Movement from Beginning to End with Frequentz 2Health News:Medical Solutions Recognized as One of 2015 Best Places to Work in Healthcare 2Health News:Medical Solutions Recognized as One of 2015 Best Places to Work in Healthcare 3Health News:Healthpointe Welcomes Dr. Gregory K. Toumayan, Chiropractor, to Colton, Temecula, and Perris 2Health News:Healthpointe Welcomes Dr. Gregory K. Toumayan, Chiropractor, to Colton, Temecula, and Perris 3
(Date:8/20/2015)... ., Aug. 20, 2015 NXT-ID, Inc. (NASDAQ: ... authentication company focused on the growing mobile commerce market ... has joined The Smart Card Alliance and the EMV ... Alliance and the Smart Card Alliance Latin America (SCALA) ... industry peers and thought leaders promoting adoption of smart ...
(Date:8/18/2015)... DUBLIN , Aug. 17, 2015 ... the addition of the "Global Biometric Authentication ... Application - Estimation & Forecast, 2015-2020" report ... biometric authentication and identification systems market is expected ... from 2015 to 2020 and generate over $25 ...
(Date:8/12/2015)... Florida , August 12, 2015 ... pace of mobile payment innovation and advanced biometrics technology ... replace the way consumers rely on using their credit ... with reinventing the future for payment services led by ... NXTD ), :  Google, Inc. (NASDAQ: GOOG ...
Breaking Biology News(10 mins):NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 2NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 3NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 4Global Biometric Authentication & Identification Market 2015: Focus On Modality, Motility & Application - Estimation & Forecasts to 2020 for the $25 Billion Industry 2Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 2Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 3Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 4Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 5Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 6
Other Contents